Adherence and HIV RNA Suppression in the Current Era of Highly Active Antiretroviral Therapy
- 1 August 2015
- journal article
- review article
- Published by Ovid Technologies (Wolters Kluwer Health) in JAIDS Journal of Acquired Immune Deficiency Syndromes
- Vol. 69 (4), 493-498
- https://doi.org/10.1097/qai.0000000000000643
Abstract
Background: We examined trends in adherence to highly active antiretroviral therapy (HAART) and HIV RNA suppression and estimated the minimum cutoff of adherence to newer HAART formulations needed for HIV RNA suppression by regimen type. Methods: We used Veterans Affairs pharmacy dispensing data from the Veterans Aging Cohort Study Virtual Cohort between October 2000 and September 2010 and defined adherence as the duration of time the patient had the medications available, relative to the total number of days between refills for all antiretrovirals in a year. Temporal trends in adherence and viral load suppression were examined by the patient's most frequently used HAART regimen in the year. The minimum needed adherence was defined as the level at which the odds of suppression was not significantly different than that observed with ≥95% adherence using repeated-measures logistic regression. Results: A total of 21,865 HAART users contributed 82,217 person-years of follow-up. There was a significant increase (Ptrend < 0.001) in the proportion virally suppressed even among those with <95% adherence (2001: 38% to 2010: 84%), and the trend was similar when restricting to their first HAART regimen. For nonnucleoside reverse transcriptase inhibitor multi-pill users, the odds of suppression did not differ for 85%–89% adherence compared to those with ≥95% adherence [odds ratios: 0.82 (0.64–1.04)], but for protease inhibitor users, the odds of suppression significantly differed if adherence levels were <95% compared to ≥95% adherence. Conclusions: Although all HIV-infected persons should be instructed to achieve perfect adherence, concerns of slightly lower adherence should not hinder prescribing new HAART regimens early in HIV infection.Keywords
This publication has 23 references indexed in Scilit:
- When to start antiretroviral therapy: as soon as possibleBMC Medicine, 2013
- U.S. Trends in Antiretroviral Therapy Use, HIV RNA Plasma Viral Loads, and CD4 T-Lymphocyte Cell Counts Among HIV-Infected Persons, 2000 to 2008Annals of Internal Medicine, 2012
- The Implications of Therapeutic Complexity on Adherence to Cardiovascular MedicationsJAMA Internal Medicine, 2011
- New antiretroviral drugs: a review of the efficacy, safety, pharmacokinetics, and resistance profile of tipranavir, darunavir, etravirine, rilpivirine, maraviroc, and raltegravirExpert Opinion on Pharmacotherapy, 2009
- Medication AdherenceCirculation, 2009
- Strategies for promoting adherence to antiretroviral therapy: a review of the literature.Current Infectious Disease Reports, 2008
- Effect of Adherence to HAART on Virologic Outcome and on the Selection of Resistance-Conferring Mutations in NNRTI- or PI-Treated PatientsHIV Research & Clinical Practice, 2007
- Development and Verification of a “Virtual” Cohort Using the National VA Health Information SystemMedical Care, 2006
- Veterans Aging Cohort Study (VACS)Medical Care, 2006
- A General Method of Compliance Assessment Using Centralized Pharmacy RecordsMedical Care, 1988